Bristol Myers Squibb Company (BMY) vs Novo Nordisk A/S (NVO)
- Bristol Myers Squibb Company BMY 59.71 −1.42%
- Novo Nordisk A/S NVO 38.83 −0.99%
Bristol Myers Squibb Company and Novo Nordisk A/S are both Drug Manufacturers General companies. Bristol Myers Squibb Company and Novo Nordisk A/S are of similar size ($131.2B and $123.7B). Novo Nordisk A/S trades at the lower P/E: 9.5× against 13.2×. Novo Nordisk A/S grew revenue faster over the last twelve months: 13.2% against 3.11%. Novo Nordisk A/S has the higher net margin (35.5% vs 18.9%) and the higher return on invested capital (28.7% vs 13.7%). Both pay a dividend; Novo Nordisk A/S yields more (4.63% vs 4.22%). Across the 23 metrics below, Novo Nordisk A/S leads on 16 and Bristol Myers Squibb Company on 7.
Valuation
Profitability
| Metric | BMY | NVO | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 70.16% | 80.73% | 72.77% |
| Operating margin | 24.22% | 43.36% | 18.77% |
| Net margin | 18.87% | 35.47% | 8.27% |
| Free cash flow margin | 23.26% | 14.79% | 17.18% |
| Return on equity | 46.63% | 60.84% | 5.87% |
| Return on assets | 10.18% | 22.00% | 2.57% |
| Return on invested capital | 13.69% | 28.67% | 6.11% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack